NCT04068649
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 2
Drug Category: Radiation Therapy
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases:
Additional Notes:
Exclusions: Participants with known brain metastases; Patients with prior radiation therapy targeting the same area for which radiation treatment is being planned
https://ClinicalTrials.gov/show/NCT04068649